Drugs / AO-176
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04445701 | Nov 2020 → Aug 2022 | plasma cell myeloma | Arch Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03834948 | Feb 2019 → Nov 2022 | neoplasm | Arch Oncology | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AO-176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03834948 ↗ |
| Modality | Monoclonal antibody | “Humanized monoclonal antibody (mAb)” NCT03834948 ↗ |
| Target | CD47 | “targeting CD47” NCT03834948 ↗ |